Prostate Cancer

Prostate cancer treatment can be detrimental to bone and muscle health, but an exercise regimen and healthy eating habits can help.

Some patients are better suited for surgery than others. In general, patients with widespread metastatic disease are also not good candidates for surgery, particularly if their cancer has spread beyond the prostate to areas like the liver, lungs, and bones.

Active surveillance can be used for many patients with prostate cancer; however, when localized, radiation therapy is an option.

Finding balance to detect and treat prostate cancer without overtreatment is important for patients.

PARP inhibitors are not only expanding the field of prostate cancer but they're giving men another option for life after cancer.

After a recommendation against routine prostate cancer screening, rates of early disease declined while the incidence of advanced disease rose. The trend highlights the difficult balance between screening and potential overtreatment.

Primed to knock out cells vulnerable due to DNA-repair problems, PARP inhibitors are ushering in a targeted-drug era in prostate cancer treatment.

VERU Inc. announced it has completed enrollment of 40 men with metastatic prostate cancer who have become resistant to at least one androgen receptor targeting agent for its phase 2 study of VERU-111.

A growing number of treatments are available to men whose prostate cancer has spread and become resistant to hormonal therapy.

Forward Momentum, a coalition launched by a biopharmaceutical company and three partners, focuses on the health disparities faced by Black men with prostate cancer.

From a new study showing that the iCanQuit smoking cessation app is more likely to work than typical guidelines, to the House unanimously passing the Veteran’s Prostate Cancer Treatment and Research Act, here’s what’s happening in the cancer landscape this week.

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.